Portfolia partner Jennifer Fried has always had a passion for bringing ideas to life in healthcare. As a venture capitalist turned “accidental entrepreneur,” now back in venture capitalism investing in...
A Complicated Journey From VC To ‘Accidental Entrepreneur’ Back To VC
Chicago-based Rising Leader Jennifer Fried spoke to In Vivo about her journey from ‘dream job’ as a VC to ‘accidental entrepreneur’ and co-founder of software company Explorer Surgical, before returning to the VC world. Now working as Portfolia’s venture partner and lead investor, Fried is scouting for innovative companies solving key women’s health issues in areas of clinical unmet needs such as menopause and endometriosis.
More from Leadership
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
• By
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.